| 摘要 |
The invention provides compounds which are pyrimidines of formula (I): wherein Ris bonded at ring position 2 and-YRis bonded at ring position 5 or 6, or YRis bonded at ring position 2 and Ris bonded at ring position 6; R is an indol-4-yl group which is substituted at the 5-or 6-position; either: (a) Y is selected from-O-(CH)-,-NH-(CH)-,.-NHC(O)-(CH)n and-C(O)NH-(CH2)-wherein n is 0 or an integer of 1 to 3, and Ris selected from an unsaturated 5-to 12-membered carbocyclic or heterocyclic group which is unsubstituted or substituted and a group-NRRwherein Rand R, which are the same or different, are each independently selected from H, C-Calkyl which is unsubstituted or substituted, C-Ccycloalkyl which is unsubstituted or substituted,-C(O)R,-C(O)N(R)and-S(O)R, or Rand R4 together form, with the nitrogen atom to which they are attached, a saturated 5-, 6-or 7-membered N-containing heterocyclic group which is unsubstituted or substituted; (b) Y is a direct bond and Ris selected from an unsaturated 5-to 12-membered carbocyclic or heterocyclic group which is unsubstituted or substituted, and a group-NR3R4 wherein Rand R, which are the same or different, are each independently selected from H, C-Calkyl which is unsubstituted or substituted, C-Ccycloalkyl which is unsubstituted or substituted,-C(O)R,-C(O)N(R)and-S(O)R; R is selected from H, C-Calkyl, C-Ccycloalkyl and a 5-to 12-membered aryl or heteroaryl group, which group is unsubstituted or substituted; and m is 1 or 2; or a pharmaceutically acceptable salt thereof. These compounds are inhibitors of PO K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PB kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.
|
